IOVANCE BIOTHERAPEUTICS, INC.
No SEC Form 4 filings for $IOVA in the last 30 days.
State Street Corporation (NYSE: STT) filed a Schedule 13G reporting beneficial ownership of 24,478,268 shares of Iovance Biotherapeutics, representing 5.5% of the class. The filing attributes shared voting power of 23,483,868 shares and shared dispositive power of 24,478,268 shares, with no sole voting or dispositive power.
Iovance Biotherapeutics (IOVA) reported Q2 2026 EPS loss of $0.11, narrower than the Zacks Consensus ($0.17). Revenue rose 66% to $99.3M, beating consensus $87.3M and guidance $86M-$88M. Amtagvi sales were $90.7M, up 68% YoY, while Proleukin was $8.6M. Shares jumped 43% after results; guidance review planned for Q3.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
Over the past 7 days, alphai's AI scored 7 news stories mentioning IOVA (IOVANCE BIOTHERAPEUTICS, INC.). Coverage has skewed bullish: 6 bullish, 1 neutral, and 0 bearish.
Recent IOVA coverage spans earnings, financial news and market movers.
New institutional ownership information may influence Iovance’s investor perception and liquidity, but the filing alone does not change fundamentals or governance control.
Beat driven by Amtagvi commercial momentum, with margin expansion and a longer cash runway, likely supports near-term upside but leaves full-year outlook under review.
Revenue acceleration in Amtagvi supports a positive fundamental narrative and can improve near-term expectations for commercial execution.
The stock’s surge is tied to a fresh earnings-style datapoint (Q2 revenue and net loss improvement) plus incremental regulatory progress for Amtagvi in Australia and expedited UK review.
The article frames a positive earnings-style surprise (narrower loss plus revenue growth) that is already moving the stock sharply intraday.
alphai scores every news story that mentions IOVA with an AI model for sentiment and relevance, and aggregates insider trades from IOVANCE BIOTHERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
State Street Corporation (NYSE: STT) filed a Schedule 13G reporting beneficial ownership of 24,478,268 shares of Iovance Biotherapeutics, representing 5.5% of the class. The filing attributes shared voting power of 23,483,868 shares and shared dispositive power of 24,478,268 shares, with no sole voting or dispositive power.
4 min readIovance Biotherapeutics (IOVA) reported Q2 2026 EPS loss of $0.11, narrower than the Zacks Consensus ($0.17). Revenue rose 66% to $99.3M, beating consensus $87.3M and guidance $86M-$88M. Amtagvi sales were $90.7M, up 68% YoY, while Proleukin was $8.6M. Shares jumped 43% after results; guidance review planned for Q3.
6 min readBiotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
3 min readIovance Biotherapeutics (NASDAQ:IOVA) shares rose sharply after the company reported Q2 revenue of $99.3 million, up 66% year over year, driven by Amtagvi. Amtagvi generated about $91 million, up 68% year over year. Net loss narrowed to $47.3 million. The company cited additional marketing approvals, including Australia, and a UK expedited review.
6 min readIovance Biotherapeutics (IOVA) shares rose about 37% after the company reported a narrower second-quarter loss, supported by strong revenue growth, according to the company. The stock was around $5.97 on Thursday, up 37.44%, after opening near $5.95 and reaching about $6.39.
2 min readIovance Biotherapeutics (NASDAQ: IOVA) reported record 2Q26 revenue of about $99.3M, up 66% YoY, with gross margin of 56%, driven by U.S. Amtagvi demand. U.S. Amtagvi revenue was about $91M. The company is reviewing FY26 revenue guidance of $350M-$370M and said FDA granted Fast Track designation for lifileucel in soft tissue sarcomas.
6 min readIOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622322d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Incr
7 min readBiotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readIovance Biotherapeutics’ shares (IOVA) are up about 74% year to date. The company’s approved melanoma therapy Amtagvi saw Q1 revenue rise 45% year over year to $71.4 million, and it has Canada approval. Analysts cited by Yahoo Finance show an average price target of $8.80 versus about $4.28. The article notes UK regulatory withdrawal for procedural reasons.
7 min readThe article cites CNBC and discusses small-cap outperformance, attributing it to AI-related capex “trickle-down” effects and portfolio broadening. It then lists 12 penny stocks under $5, using Finviz and Insider Monkey data. It highlights Prospect Capital (PSEC) investing in ShipOffers and Iovance (IOVA) updating TIL therapy progress, including cash of ~$319M and revenue guidance of $350M–$370M.
6 min read
